tetano
Editor, Senior Moderator
Int J Infect Dis
. 2021 Oct 12;S1201-9712(21)00798-0.
doi: 10.1016/j.ijid.2021.10.012. Online ahead of print.
The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients
Zainab Thanon Hasan[SUP] 1 [/SUP], Dr Mohammed Qasim Yahya Mal Allah Al Atrakji[SUP] 2 [/SUP], Dr Ahmed Kayes Mehuaiden[SUP] 3 [/SUP]
Affiliations
Abstract
The purpose of this study is to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19).
Methods: This single-center, prospective, randomized clinical trial was conducted from 1 December 2020 to 1 June 2021 at Al-Shifaa hospital in Mosul, Iraq. There were 158 patients with severe COVID-19 included in the study, 82 in the melatonin group (who received 10 mg melatonin in addition to standard therapeutic care), and 76 in the control group (given standard therapeutic care only). Patients were chosen by blocked randomization design. The physician then evaluated and recorded the incidence of thrombosis, sepsis, and mortality rate on days 5, 11, and 17 of symptoms.
Results: The intervention group consisted of 82 patients, while the control group consisted of 76 patients. In comparison to the control group, thrombosis and sepsis developed significantly less frequently (P < 0.05) in the melatonin group during the second week of infection, while mortality was significantly higher in the control group (P < 0.05).
Conclusions: Adjuvant use of Melatonin may help reduce thrombosis, sepsis, and mortality in COVID-19 patients.
Keywords: COVID-19; Clinical trial; Melatonin.
. 2021 Oct 12;S1201-9712(21)00798-0.
doi: 10.1016/j.ijid.2021.10.012. Online ahead of print.
The Effect of Melatonin on Thrombosis, Sepsis and Mortality Rate in COVID-19 Patients
Zainab Thanon Hasan[SUP] 1 [/SUP], Dr Mohammed Qasim Yahya Mal Allah Al Atrakji[SUP] 2 [/SUP], Dr Ahmed Kayes Mehuaiden[SUP] 3 [/SUP]
Affiliations
- PMID: 34653660
- DOI: 10.1016/j.ijid.2021.10.012
Abstract
The purpose of this study is to determine the effect of melatonin on thrombosis, sepsis, and mortality rate in adult patients with severe coronavirus infection (COVID-19).
Methods: This single-center, prospective, randomized clinical trial was conducted from 1 December 2020 to 1 June 2021 at Al-Shifaa hospital in Mosul, Iraq. There were 158 patients with severe COVID-19 included in the study, 82 in the melatonin group (who received 10 mg melatonin in addition to standard therapeutic care), and 76 in the control group (given standard therapeutic care only). Patients were chosen by blocked randomization design. The physician then evaluated and recorded the incidence of thrombosis, sepsis, and mortality rate on days 5, 11, and 17 of symptoms.
Results: The intervention group consisted of 82 patients, while the control group consisted of 76 patients. In comparison to the control group, thrombosis and sepsis developed significantly less frequently (P < 0.05) in the melatonin group during the second week of infection, while mortality was significantly higher in the control group (P < 0.05).
Conclusions: Adjuvant use of Melatonin may help reduce thrombosis, sepsis, and mortality in COVID-19 patients.
Keywords: COVID-19; Clinical trial; Melatonin.